lamivudine + raltegravir

Lamivudine + raltegravir is a dual antiretroviral therapy (ART) regimen investigated for the maintenance of virological suppression in patients living with HIV-1. This combination consists of lamivudine (300 mg), a nucleoside reverse transcriptase inhibitor (NRTI), and raltegravir (1200 mg), an integrase strand transfer inhibitor (INSTI). The regimen is primarily studied as a simplification strategy for patients who are already virologically suppressed but seek to reduce drug-related toxicity, pill burden, or potential drug-drug interactions associated with standard triple-therapy regimens. By utilizing a high-dose, once-daily raltegravir formulation alongside lamivudine, the therapy aims to provide a potent, well-tolerated alternative for long-term HIV management. The RALAM-II Phase 3b trial, led by Judit Pich at the Hospital Clínic de Barcelona, specifically evaluates this dual therapy in patients experiencing inconvenience or toxicity with their current regimens.

Brand names

Dutrebis

Other names

Lamivudine and Raltegravir dual therapyLamivudine/Raltegravir